Search Site

Trends banner

Tesla sales tumble in Europe in Q1

The company suffered from boycotts against the policies of Elon Musk.

Ford’s US Q1 auto sales dip

But its Q1 figures exceed a forecast by Edmunds

Vanke reports annual loss of $6.8 bn

The property giant attributes loss to falling sales and shrinking profit.

Goldwind 2024 revenue up 12.5%

The clean energy giant posted $7.8bn in revenue for 2024.

Emaar to pay $2.39bn dividend

The company had posted $19bn in property sales for 2024.

Avalon sets sights on Tadawul listing

The final Offer Price will be determined at the end of the book-building process. (Avalon)
  • The book-building process for Avalon Pharma's IPO will commence on January 14th and conclude on January 18th.
  • In the event that there is sufficient demand by Individual Investors, the number of shares initially allocated to participating parties will be reduced to 5.4 million shares.

Riyadh, Saudi Arabia — Middle Eastern pharmaceutical firm Avalon Pharma has announced its intention to float on the Saudi Exchange’s main market, offering 6 million shares, representing 30 percent of its issued share capital, in its initial public offering.

The book-building process for Avalon Pharma’s IPO will commence on January 14th and conclude on January 18th.

The company said in a statement that in the event that there is sufficient demand by Individual Investors, the number of shares initially allocated to participating parties will be reduced to 5.4 million shares, representing 90 percent of the total offering.

“This IPO is a historic moment for Avalon Pharma,” said CEO Dr. Omar Hassan.

“The Saudi healthcare sector is experiencing unprecedented growth, and we are confident that our listing on the Tadawul will enable us to capitalize on this momentum. The capital raised will fuel our expansion plans, allowing us to bring more effective and affordable medications to families across the Kingdom,” he said.

Headquartered in Riyadh, Saudi Arabia, the company exports its products to over 10 countries across the Middle East and North Africa and is one of the fastest growing consumer pharma companies in Saudi Arabia.